Apatinib for advanced sarcoma: results from multiple institutions’ off-label use in China

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group

(2016) Anna Patrikidou et al.   EUROPEAN JOURNAL OF CANCER

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

(2016) Javier Martin-Broto et al.   JOURNAL OF CLINICAL ONCOLOGY

Apatinib in Advanced Gastric Cancer: A Doubtful Step Forward

(2016) Lorenzo Fornaro et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction

(2016) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Outcome of Patients With Recurrent Osteosarcoma Enrolled in Seven Phase II Trials Through Children's Cancer Group, Pediatric Oncology Group, and Children's Oncology Group: Learning From the Past to Move Forward

(2016) Joanne P. Lagmay et al.   JOURNAL OF CLINICAL ONCOLOGY

Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial

(2016) William D Tap et al.   LANCET

Soft tissue sarcoma – A review of presentation, management and outcomes in 110 patients

(2016) Robert Bains et al.   SURGEON-JOURNAL OF THE ROYAL COLLEGES OF SURGEONS OF EDINBURGH AND IRELAND

Refinements in Sarcoma Classification in the Current 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone

(2016) Vickie Y. Jo et al.   Surgical Oncology Clinics of North America

Study protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trial

(2015) Thomas Brodowicz et al.   BMC CANCER

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial

(2015) Giovanni Grignani et al.   LANCET ONCOLOGY

A phase 2 trial of R1507, a monoclonal antibody to the insulin-like growth factor-1 receptor (IGF-1R), in patients with recurrent or refractory rhabdomyosarcoma, osteosarcoma, synovial sarcoma, and other soft tissue sarcomas: Results of a Sarcoma Alliance

(2014) Alberto S. Pappo et al.   CANCER

Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer: Results From a Randomized, Placebo-Controlled, Parallel-Arm, Phase II Trial

(2013) Jin Li et al.   JOURNAL OF CLINICAL ONCOLOGY

Insulin Growth Factor-Receptor (IGF-1R) Antibody Cixutumumab Combined with the mTOR Inhibitor Temsirolimus in Patients with Refractory Ewing's Sarcoma Family Tumors

(2012) A. Naing et al.   CLINICAL CANCER RESEARCH

Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial

(2012) Winette TA van der Graaf et al.   LANCET

Phase II Study of Sequential Gemcitabine Followed by Docetaxel for Recurrent Ewing Sarcoma, Osteosarcoma, or Unresectable or Locally Recurrent Chondrosarcoma: Results of Sarcoma Alliance for Research Through Collaboration Study 003

(2012) E. Fox et al.   ONCOLOGIST

A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study

(2011) G. Grignani et al.   ANNALS OF ONCOLOGY

Randomized Phase II Study Comparing Gemcitabine Plus Dacarbazine Versus Dacarbazine Alone in Patients With Previously Treated Soft Tissue Sarcoma: A Spanish Group for Research on Sarcomas Study

(2011) Xavier García-del-Muro et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

(2010) Jin Li et al.   BMC CANCER

A Phase 1 Trial and Pharmacokinetic Study of Cediranib, an Orally Bioavailable Pan–Vascular Endothelial Growth Factor Receptor Inhibitor, in Children and Adolescents With Refractory Solid Tumors

(2010) Elizabeth Fox et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinician versus nurse symptom reporting using the National Cancer Institute--Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient's self-reported questionnaire

(2009) M. Cirillo et al.   ANNALS OF ONCOLOGY

Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)

(2009) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Weekly Paclitaxel for Unresectable Angiosarcoma: The ANGIOTAX Study

(2008) Nicolas Penel et al.   JOURNAL OF CLINICAL ONCOLOGY

Changes in Incidence and Survival of Ewing Sarcoma Patients Over the Past 3 Decades

(2008) Natia Esiashvili et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY